儿童注意缺陷多动障碍药物依从性及影响因素

doi:10.11852/zgetbjzz2018-26-10-14

中国儿童保健杂志 ›› 2018, Vol. 26 ›› Issue (10): 1096-1099.DOI: 10.11852/zgetbjzz2018-26-10-14

儿童注意缺陷多动障碍药物依从性及影响因素

赵秋霞, 陈立

重庆医科大学附属儿童医院儿童青少年生长发育与心理健康中心;儿童发育疾病研究教育部重点实验室,重庆 400014

收稿日期:2018-04-19 发布日期:2018-10-10 出版日期:2018-10-10
通讯作者: 陈立,E-mail:chenli2012@126.com
作者简介:赵秋霞(1991-),女,云南人,住院医师,硕士研究生,主要研究方向为注意缺陷多动障碍。
基金资助:
重庆市高等教育学会2015-2016年度高等教育科学研究课题(CQGJ153583B);重庆医科大学附属儿童医院转化医学项目(zhyx2012-2)

Status and influencing factors of medication compliance in children with attention deficit hyperactivity disorder

ZHAO Qiu-xia, CHEN Li

Division of Children and Adolescents Growth and Development & Mental Health,Children′s Hospital of Chongqing Medical University,Ministry of Education Key Laboratory of Child Development and Disorders,Chongqing 400014,China

Received:2018-04-19 Online:2018-10-10 Published:2018-10-10
Contact: CHEN Li,E-mail:chenli2012@126.com

摘要/Abstract

摘要： 注意缺陷多动障碍(ADHD)是儿童和青少年期最常见的神经发育障碍,约影响全世界5%～11%的儿童。药物治疗是6岁以上ADHD儿童首选方案,约70%患者药物治疗有效。多种药物已被应用于ADHD临床治疗,如盐酸哌甲酯和苯丙胺、盐酸托莫西汀及可乐定和胍法辛等。药物副作用、药物剂型、患儿生长速度、家庭因素、患儿用药体验、睡眠问题或障碍等多种因素均会影响药物依从性。医生、父母和患儿共享信息、商讨治疗方案、监测疗效和副作用,并积极开展医教结合、家校结合,实施行为管理和干预,有助于提高依从性、改善治疗效果,促进患儿学业成绩及社会功能、生活质量全面提升。

关键词: 注意缺陷多动障碍, 药物治疗, 依从性, 影响因素

Abstract: Attention deficit hyperactivity disorder (ADHD) is the most common neuro-developmental disorder,which affects 5%~11% children around the world.Medication therapy is the preferred treatment for children aged over 6 years old with ADHD.It is considered that medication is effective for 70% of ADHD children.A variety of drugs have been used,such as methylphenidate and amphetamine,atomoxetine,guanfacine and clonidine.Medication adherence can be influenced by many factors,such as side effects of drugs,dosage form,growth velocity,families,and patients′ experience of taking medication,as well as sleep disorders.Doctors,parents and children cooperate to share information,decide on the medication treatment plan,monitor the effect of drug treatment and side effects,and actively carry out the combination of medical education and home school to implement behavior management and intervention,which will significantly improve the compliance,improve the treatment effect of medication treatment,promote the study of children with ADHD,improve overall promotion of social function and quality of life.

Key words: attention deficit hyperactivity disorder, pharmacotherapy, medication compliance, influencing factors

中图分类号:

R179

赵秋霞, 陈立. 儿童注意缺陷多动障碍药物依从性及影响因素[J]. 中国儿童保健杂志, 2018, 26(10): 1096-1099.

ZHAO Qiu-xia, CHEN Li. Status and influencing factors of medication compliance in children with attention deficit hyperactivity disorder[J]. journal1, 2018, 26(10): 1096-1099.

0
/ / 推荐

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://manu41.magtech.com.cn/Jwk_zgetbjzz/CN/10.11852/zgetbjzz2018-26-10-14

https://manu41.magtech.com.cn/Jwk_zgetbjzz/CN/Y2018/V26/I10/1096

参考文献

[1] Dalsgaard S,Leckman JF,Mortensen PB,et al.Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder:a prospective cohort study[J].Lancet Psychiatry,2015,8(2):702-709.
[2] Centers for Disease Control and Prevention.Attention-deficit/hyperactivity disorder (ADHD):facts about ADHD[EB/OL].[2014-08-22]http://www.cdc.gov/ncbddd/adhd/facts.html.
[3] 郑毅,刘婧.中国注意缺陷多动障碍防治指南[M].2版.北京:中华医学电子音像出版社,2015.
[4] Wolraich M.ADHD:clinical practice guideline for the diagnosis,evaluation,and treatment of attention-deficit/hyperactivity disorder in children and adolescents[J].Pediatrics,2011,128(5):1007-1022.
[5] Ahmed R,Aslani P.Attention-defcit/hyperactivity disorder:an update on medication adherence and persistence in children,adolescents and adults[J].Expert Rev Pharmacoecon Outcomes Res,2013,13:791-815.
[6] De Sousa A,Kalra G.Drug therapy of attention deficit hyperactivity disorder:current trends[J].Mens Sana Monogr,2012,10(1):45-69.
[7] Sharma A, Couture J.A review of the pathophysiology,etiology,and treatment of attention-deficit hyperactivity disorder (ADHD)[J].Ann Pharmacother,2014,48(2):209-225.
[8] Wehmeier PM,Dittmann RW,Banaschewski T.Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice:Results from the COMPLY observational study[J].Atten Defic Hyperact Disord,2015,7(2):165-174.
[9] Cortese S,Holtmann M,Banaschewski T,et al.Practitioner review:current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents[J].Child Psychol Psychiatry,2013,54(3):227-246.
[10] Garg J, Arun P, Chavan BS.Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder[J].Indian Pediatr,2014,51(7):550-554.
[11] Hanwella R.Senanayake M,de Silva V.Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents:a meta-analysis[J].BMC Psychiatry,2011,11:176.
[12] Tzang RF,Wang YC.Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit/hyperactivity disorder[J].Psychiatry Clin Neurosci,2012,66(1):53-63.
[13] Childress AC,Kollins SH,Marraffino A,et al.Efficacy,safety,and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting[J].J Child Adolesc Psychopharmacol,2017,27(1):66-74.
[14] Poulton AS.Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder:a prospective cohort study[J].Int Clin Psychopharmacol,2016,31(2):93-99.
[15] Kratochvil CJ,Wilens TE,Greenhill LL,et al.Effects of longtermatomoxetine treatment for young children with attentiondeficit/hyperactivity disorder[J].Am Acad Child Adolesc Psychiatry,2006,45:919-927.
[16] Graham J,Bcanascheewski T,Buitelaar J,et al.European guidelines on managing adverse effects of medication for ADHD[J].Eur Child Adolesc Psychiatry,2011,20:17-37.
[17] Wigal SB,Childress A, Berry SA,et al.Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/Hyperactivity disorder[J].Child Adolesc Psychopharmacol,2017,27(8):690-699.
[18] Cheng JY,Ronald YL, Johnh SN, et al.Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis[J].Psychopharmacology,2007,194(2):197-209.
[19] Habel LA,Cooper WO,Sox CM,et al.ADHD medications and risk of serious cardiovascular events in young and middle-aged adults[J].JAMA,2011,306(24):2673-2683.
[20] Sayer GR.Acute and long-term cardiovascular effects of stimulant,guanfacine,and combination therapy for attention-deficit/hyperactivity disorder[J].Child Adolesc Psychopharmacol,2016,26(10):882-888.
[21] Cortese S,Pauei P,Arcieri R,et al.Safety of methylphenidate and atomoxetine in children with attention-deficit/hyperactivity disorder (ADHD):data from the Italian National ADHD Registry[J].CNS Drugs,2015,29(10):865-877.
[22] 范琼丽,陈立.注意缺陷多动障碍患儿共患睡眠问题和睡眠障碍的研究进展[J].中国实用儿科杂志,2016,31(5):391-395.
[23] Storebo OJ,Ramstad E,Krogh HB,et al.Methylphenidate for children and adolescents with attention deficit hyperactivity disorder(ADHD)[J].Cochrane Database Syst Rev,2015,11:CD009885.
[24] Becker SP,Froehlich TE,Epstein JN,et al.Effects of methyphenidate on sleep functioning in children with attention-deficit/hyperactivity disorder.[J].J Dev Behav Pediatr,2016,37(5):395-404.
[25] Hiscock H,Sciberras E,Mensah F,et al.Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder,and parental mental health:randomised controlled trial[J].BMJ,2015,350:h68.
[26] Hodgkins P,Sasane′ R,Christensen L,et al.Treatment outcomes with methylphenidate formulations among patients with ADHD:retrospective claims analysis of a managed care population[J].Curr Med Res Opin,2011,Suppl 2:53-62.
[27] Palli SR,Kamble PS,Chen H,et al.Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder[J].Child Adolesc Psychopharmacol,2012,22(2):139-148.
[28] Bai GN,Wang YF,Niu WY,et al.Effectiveness of a focused,brief psychoeducation program for parents of ADHD children:improvement of medication adherence and symptoms[J].Neuropsychiatr Dis Treat,2015,11:2721-2735.

儿童注意缺陷多动障碍药物依从性及影响因素

Status and influencing factors of medication compliance in children with attention deficit hyperactivity disorder

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李荣, 李年, 吴丹丹, 黄荣, 陈银花. 盐酸哌甲酯缓释片对注意缺陷多动障碍儿童生长的影响[J]. 中国儿童保健杂志, 2023, 31(7): 731-735.
[2]	张婕, 安英萍, 杨毅, 张艳楠, 田琳. 从全生命周期视角识别和治疗注意缺陷多动障碍女童和女性的专家共识(2020年版)解读[J]. 中国儿童保健杂志, 2023, 31(5): 570-575.
[3]	易文霞, 陈立. 注意缺陷多动障碍儿童父母养育压力研究进展[J]. 中国儿童保健杂志, 2023, 31(4): 408-411.
[4]	刘芮卓, 陈立. 儿童注意缺陷多动障碍与肥胖的相关性研究[J]. 中国儿童保健杂志, 2023, 31(4): 412-415.
[5]	彭莲华, 刘冬冬, 龙楠楠, 徐萍, 陈阳, 毛平. 童年不良经历青少年执行功能现状及影响因素研究进展[J]. 中国儿童保健杂志, 2023, 31(3): 299-303.
[6]	朱笑彤, 任园春, 刘靖, 李雪, 王芳, 尹婷妮, 谢永涛, 宋懿芪, 范碧瑶, 吉宁. 注意缺陷多动障碍小学生精细动作发展特点研究[J]. 中国儿童保健杂志, 2023, 31(3): 322-326.
[7]	周梅君, 魏蓉美, 袁晓玲, 赵婷, 赵硕. 小组训练对学龄前注意缺陷多动障碍儿童注意品质的干预效果[J]. 中国儿童保健杂志, 2023, 31(3): 336-340.
[8]	黄琦, 黄欣欣, 钱沁芳, 王章琼, 李国凯. 注意缺陷多动障碍共患发育性协调障碍的学龄前儿童智力结构特征[J]. 中国儿童保健杂志, 2023, 31(2): 136-140.
[9]	梅练妮, 胡纯纯, 徐琼. 脆性X综合征药物治疗进展[J]. 中国儿童保健杂志, 2023, 31(2): 180-184.
[10]	柴润玉, 王康程, 林华伟, 张俊英, 邢婕, 张华, 曹爱华. 注意缺陷多动障碍儿童及其父母攻击行为相互作用的网络分析[J]. 中国儿童保健杂志, 2022, 30(8): 845-850.
[11]	邓岚柳, 陈立. 药物治疗对注意缺陷多动障碍患儿体格生长影响的研究进展[J]. 中国儿童保健杂志, 2022, 30(8): 874-878.
[12]	张颖, 王俊峰, 丁艳华. 儿童语言发育迟缓的临床特征和影响因素研究[J]. 中国儿童保健杂志, 2022, 30(8): 912-915.
[13]	房海波, 王荣, 褚琳娜, 冯艳芳, 白容荣, 郭丰桐. 血清维生素D水平与伴中央颞区棘波的儿童良性癫痫共患注意缺陷多动障碍患儿认知功能的相关性分析[J]. 中国儿童保健杂志, 2022, 30(7): 775-778.
[14]	陈书进, 吴丹丹, 李晓南. 注意缺陷多动障碍和肥胖共病机制的研究进展[J]. 中国儿童保健杂志, 2022, 30(4): 401-404.
[15]	方圆, 孔维延, 马晨欢, 潘丽珠, 朱佩滢, 王瑜. 注意缺陷多动障碍儿童过敏性疾病发生情况的调查[J]. 中国儿童保健杂志, 2022, 30(4): 431-435.